Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

In a major advancement for ovarian cancer research, a team of scientists from the University of Pittsburgh has identified ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...

According to a new analysis of a population index, the use of oral contraceptives, aka birth control, and a greater number of ...

Results from Phase 2 RAINFOL TM -01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m 2 led to a confirmed objective response rate (ORR) of 55.6% and median ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Elizabeth K. Lee, MD, a medical oncologist in the gynecologic oncology program at Dana-Farber, presented results from a phase ...

Imagine a world where bacteria, typically feared for causing disease, are turned into powerful weapons against cancer. That's ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...

Jessica Wozniak thought that some of the symptoms of norovirus were lingering. They were signs of Stage 4 colon cancer.